Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%

Moderna and Merck have announced top-line results from a trial of their mRNA cancer vaccine, showing a 42% reduction in death and recurrence rates. This follows their previous report of the trial's success. No further details on the specifics of the trial or the vaccine's mechanism of action have been provided.